Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech,” which highlights how late-stage drug development assets increasingly drive valuation in the biopharma sector. The editorial, supported by analysis from McKinsey & Company, notes that companies tend to realize the majority of value creation as products approach commercialization, reflecting reduced risk and clearer revenue visibility, a trend directly relevant to Oncotelic’s oncology-focused pipeline and strategic development approach.
To view the full press release, visit https://nnw.fm/42BlH.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The Company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The Company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.
For more information, visit the company’s newsroom at https://nnw.fm/OTLC.
